Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Diabetes

Free Subscription Articles published in Lancet Retrieve available abstracts of 71 articles: HTML format

Single Articles

March 2024
1. BROWN DM, Boyer DS, Do DV, Wykoff CC, et al
   Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
   Lancet. 2024 Mar 7:S0140-6736(23)02577-1. doi: 10.1016/S0140-6736(23)02577.
   PubMed     Abstract available
   
   
   
2. GABRIELLE PH, Creuzot-Garcher C
   Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
   Lancet. 2024 Mar 7:S0140-6736(23)02760-5. doi: 10.1016/S0140-6736(23)02760.
   PubMed    
   
   
   January 2024
3. THE LANCET
   Treating obesity and diabetes: drugs alone are not enough.
   Lancet. 2024;403:1.
   PubMed    
   
   
   November 2023
4. HEERSPINK HJL, Kiyosue A, Wheeler DC, Lin M, et al
   Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
   Lancet. 2023 Nov 2:S0140-6736(23)02230-4. doi: 10.1016/S0140-6736(23)02230.
   PubMed     Abstract available
   
   
   
5. ZHAO X, Duaso M, Ghazaleh HA, Cheng L, et al
   Effectiveness of interventions for improving physical activity level in working-age people (aged 18-60 years) with type 2 diabetes: a systematic review and meta-analysis.
   Lancet. 2023;402 Suppl 1:S97.
   PubMed     Abstract available
   
   
   
6. SPENCER LH, Albustami M, Porter A, Naha G, et al
   Uptake of diabetes follow-up checks by minority community groups: a rapid review of the evidence for the CYMELL study.
   Lancet. 2023;402 Suppl 1:S86.
   PubMed     Abstract available
   
   
   
7. EVANS J, White P, Ha H
   Evaluating the effectiveness of community health worker interventions on glycaemic control in type 2 diabetes: a systematic review and meta-analysis.
   Lancet. 2023;402 Suppl 1:S40.
   PubMed     Abstract available
   
   
   
8. BOZKURT D, Duaso M, Sturt J
   Use of the 2021 UK Medical Research Council guidance to refine the Women's Wellness with Type 2 Diabetes Programme: a mixed-methods study.
   Lancet. 2023;402 Suppl 1:S27.
   PubMed     Abstract available
   
   
   
9. SINGH M, Wambua S, Lee SI, Okoth K, et al
   Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
   Lancet. 2023;402 Suppl 1:S84.
   PubMed     Abstract available
   
   
   
10. PIDD K, Breeze P, Pollard D, Ahern A, et al
    Estimation of HbA(1c) after weight loss using a beta-regression for an economic evaluation of a behavioural weight management programme from the GLoW trial: a methodological study.
    Lancet. 2023;402 Suppl 1:S75.
    PubMed     Abstract available
    
    
    
11. GEDEON E, Henderson M, Leyland AH, Allik M, et al
    Association between care experience and mental health hospitalisation among children in Scotland, with a focus on chronic conditions (CHiCS): a population-wide longitudinal study using administrative data.
    Lancet. 2023;402 Suppl 1:S5.
    PubMed     Abstract available
    
    
    
12. AYOUB A, Akyea RK, L'Esperance V, Ayis S, et al
    Determinants of lipid clinic referral and attendance in a multi-ethnic adult population in south London: a cross-sectional study.
    Lancet. 2023;402 Suppl 1:S26.
    PubMed     Abstract available
    
    
    October 2023
13. HINKLE SN, Mumford SL, Grantz KL, Mendola P, et al
    Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study.
    Lancet. 2023 Oct 19:S0140-6736(23)01517-9. doi: 10.1016/S0140-6736(23)01517.
    PubMed     Abstract available
    
    
    
14. RUSSELL-JONES D, Babazono T, Cailleteau R, Engberg S, et al
    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
    Lancet. 2023 Oct 17:S0140-6736(23)02179-7. doi: 10.1016/S0140-6736(23)02179.
    PubMed     Abstract available
    
    
    
15. SHAH AS, Wolf RM
    Weekly insulin: a paradigm shift in type 1 diabetes therapy.
    Lancet. 2023 Oct 17:S0140-6736(23)02227-4. doi: 10.1016/S0140-6736(23)02227.
    PubMed    
    
    
    
16. KIVUYO S, Birungi J, Okebe J, Wang D, et al
    Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.
    Lancet. 2023;402:1241-1250.
    PubMed     Abstract available
    
    
    
17. KISIGO GA, Peck RN
    Integrating HIV, hypertension, and diabetes primary care in Africa.
    Lancet. 2023;402:1211-1213.
    PubMed    
    
    
    August 2023
18. NAUCK MA, Horowitz M
    Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists.
    Lancet. 2023;402:429-431.
    PubMed    
    
    
    June 2023
19. ROSENSTOCK J, Frias J, Jastreboff AM, Du Y, et al
    Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Lancet. 2023 Jun 26:S0140-6736(23)01053-X. doi: 10.1016/S0140-6736(23)01053.
    PubMed     Abstract available
    
    
    
20. BAIN SC, Min T
    A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena.
    Lancet. 2023 Jun 26:S0140-6736(23)01182-0. doi: 10.1016/S0140-6736(23)01182.
    PubMed    
    
    
    
21. GARVEY WT, Frias JP, Jastreboff AM, le Roux CW, et al
    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi: 10.1016/S0140-6736(23)01200.
    PubMed     Abstract available
    
    
    
22. FRANDSEN CS, Madsbad S
    SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide.
    Lancet. 2023 Jun 26:S0140-6736(23)01292-8. doi: 10.1016/S0140-6736(23)01292.
    PubMed    
    
    
    
23. THE LANCET
    Diabetes: a defining disease of the 21st century.
    Lancet. 2023;401:2087.
    PubMed    
    
    
    
24. FRIAS JP, Hsia S, Eyde S, Liu R, et al
    Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
    Lancet. 2023 Jun 23:S0140-6736(23)01302-8. doi: 10.1016/S0140-6736(23)01302.
    PubMed     Abstract available
    
    
    
25. APOVIAN CM, McDonnell ME
    CagriSema and the link between obesity and type 2 diabetes.
    Lancet. 2023 Jun 23:S0140-6736(23)01291-6. doi: 10.1016/S0140-6736(23)01291.
    PubMed    
    
    
    
26. FRIAS JP, Deenadayalan S, Erichsen L, Knop FK, et al
    Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
    Lancet. 2023 Jun 23:S0140-6736(23)01163-7. doi: 10.1016/S0140-6736(23)01163.
    PubMed     Abstract available
    
    
    
27. ARODA VR, Aberle J, Bardtrum L, Christiansen E, et al
    Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
    Lancet. 2023 Jun 23:S0140-6736(23)01127-3. doi: 10.1016/S0140-6736(23)01127.
    PubMed     Abstract available
    
    
    
28. SHERRILL CH, Hwang AY
    The pursuit of optimal semaglutide dosing in type 2 diabetes continues.
    Lancet. 2023 Jun 23:S0140-6736(23)01233-3. doi: 10.1016/S0140-6736(23)01233.
    PubMed    
    
    
    
29. KNOP FK, Aroda VR, do Vale RD, Holst-Hansen T, et al
    Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 23:S0140-6736(23)01185-6. doi: 10.1016/S0140-6736(23)01185.
    PubMed     Abstract available
    
    
    
30. WATKINS DA, Ali MK
    Measuring the global burden of diabetes: implications for health policy, practice, and research.
    Lancet. 2023 Jun 22:S0140-6736(23)01287-4. doi: 10.1016/S0140-6736(23)01287.
    PubMed    
    
    
    
31. WALKER AF, Graham S, Maple-Brown L, Egede LE, et al
    Interventions to address global inequity in diabetes: international progress.
    Lancet. 2023 Jun 22:S0140-6736(23)00914-5. doi: 10.1016/S0140-6736(23)00914.
    PubMed     Abstract available
    
    
    
32. AGARWAL S, Wade AN, Mbanya JC, Yajnik C, et al
    The role of structural racism and geographical inequity in diabetes outcomes.
    Lancet. 2023 Jun 22:S0140-6736(23)00909-1. doi: 10.1016/S0140-6736(23)00909.
    PubMed     Abstract available
    
    
    
33. 
    Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2023 Jun 22:S0140-6736(23)01301-6. doi: 10.1016/S0140-6736(23)01301.
    PubMed     Abstract available
    
    
    
34. DAVIES MJ, Ahmad E, Lim S, Lamptey R, et al
    Cancer is becoming the leading cause of death in diabetes - Authors' reply.
    Lancet. 2023;401:1849-1850.
    PubMed    
    
    
    
35. WANG M, Sperrin M, Rutter MK, Renehan AG, et al
    Cancer is becoming the leading cause of death in diabetes.
    Lancet. 2023;401:1849.
    PubMed    
    
    
    May 2023
36. MATHIEU C, Asbjornsdottir B, Bajaj HS, Lane W, et al
    Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
    Lancet. 2023 May 5:S0140-6736(23)00520-2. doi: 10.1016/S0140-6736(23)00520.
    PubMed     Abstract available
    
    
    
37. CONRAD N, Misra S, Verbakel JY, Verbeke G, et al
    Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
    Lancet. 2023 May 5:S0140-6736(23)00457-9. doi: 10.1016/S0140-6736(23)00457.
    PubMed     Abstract available
    
    
    April 2023
38. VERRASTRO O, Panunzi S, Castagneto-Gissey L, De Gaetano A, et al
    Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00634-7. doi: 10.1016/S0140-6736(23)00634.
    PubMed     Abstract available
    
    
    
39. QUATTRIN T, Mastrandrea LD, Walker LSK
    Type 1 diabetes.
    Lancet. 2023 Apr 5:S0140-6736(23)00223-4. doi: 10.1016/S0140-6736(23)00223.
    PubMed     Abstract available
    
    
    March 2023
40. GREGG EW, Buckley J, Ali MK, Davies J, et al
    Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact.
    Lancet. 2023 Mar 14:S0140-6736(23)00001-6. doi: 10.1016/S0140-6736(23)00001.
    PubMed     Abstract available
    
    
    February 2023
41. PERDOMO CM, Cohen RV, Sumithran P, Clement K, et al
    Contemporary medical, device, and surgical therapies for obesity in adults.
    Lancet. 2023 Feb 9:S0140-6736(22)02403-5. doi: 10.1016/S0140-6736(22)02403.
    PubMed     Abstract available
    
    
    November 2022
42. BURKI T
    HPV and diabetes researchers win Prince Mahidol Awards.
    Lancet. 2022;400:1837-1838.
    PubMed    
    
    
    
43. 
    Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02074.
    PubMed     Abstract available
    
    
    
44. AHMAD E, Lim S, Lamptey R, Webb DR, et al
    Type 2 diabetes.
    Lancet. 2022 Nov 1. pii: S0140-6736(22)01655.
    PubMed     Abstract available
    
    
    
45. BUSH KJ, Papacosta AO, Lennon L, Rankin J, et al
    The influence of neighbourhood-level socioeconomic deprivation on developing type 2 diabetes in older men: a longitudinal analysis of the British Regional Heart Study cohort data.
    Lancet. 2022;400 Suppl 1:S26.
    PubMed     Abstract available
    
    
    October 2022
46. URVA S, Coskun T, Loh MT, Du Y, et al
    LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
    Lancet. 2022 Oct 27. pii: S0140-6736(22)02033.
    PubMed     Abstract available
    
    
    
47. MYERS B, Lombard CJ, Lund C, Joska JA, et al
    Comparing dedicated and designated approaches to integrating task-shared psychological interventions into chronic disease care in South Africa: a three-arm, cluster randomised, multicentre, open-label trial.
    Lancet. 2022;400:1321-1333.
    PubMed     Abstract available
    
    
    August 2022
48. CONRAD N, Verbeke G, Molenberghs G, Goetschalckx L, et al
    Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01349.
    PubMed     Abstract available
    
    
    
49. VADUGANATHAN M, Docherty KF, Claggett BL, Jhund PS, et al
    SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01429.
    PubMed     Abstract available
    
    
    
50. TUTTLE KR, Rangaswami J
    SGLT2 inhibitors as the bedrock of therapy for heart failure.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01584.
    PubMed    
    
    
    
51. TESFAYE S, Sloan G, Petrie J, White D, et al
    Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, rando
    Lancet. 2022 Aug 22. pii: S0140-6736(22)01472.
    PubMed     Abstract available
    
    
    June 2022
52. GOLUBIC R, Barber TM, Caleyachetty R
    Obesity definition for personalised treatment of type 2 diabetes.
    Lancet. 2022;399:2189.
    PubMed    
    
    
    
53. LINGVAY I, Sumithran P, Cohen RV, Roux CWL, et al
    Obesity definition for personalised treatment of type 2 diabetes Authors' reply.
    Lancet. 2022;399:2189-2190.
    PubMed    
    
    
    May 2022
54. DASHRAATH P, Chen K, Htet ZW, Chan SY, et al
    Pre-eclampsia with paradoxical polyuria: diabetes insipidus in pregnancy.
    Lancet. 2022;399:1809.
    PubMed    
    
    
    March 2022
55. ALESSI J, Yankiv M
    War in Ukraine and barriers to diabetes care.
    Lancet. 2022 Mar 21. pii: S0140-6736(22)00480.
    PubMed    
    
    
    February 2022
56. WATTS G
    Viroj Tangcharoensathien: master carpenter of Thai health care.
    Lancet. 2022;399:e9.
    PubMed    
    
    
    
57. TUCHMAN A
    Diabetes and race in the USA over the past century.
    Lancet. 2022;399:712-713.
    PubMed    
    
    
    January 2022
58. WYKOFF CC, Abreu F, Adamis AP, Basu K, et al
    Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00018.
    PubMed     Abstract available
    
    
    November 2021
59. BHUTTA ZA, Salam RA, Gomber A, Lewis-Watts L, et al
    A century past the discovery of insulin: global progress and challenges for type 1 diabetes among children and adolescents in low-income and middle-income countries.
    Lancet. 2021;398:1837-1850.
    PubMed     Abstract available
    
    
    
60. NAZARZADEH M, Bidel Z, Canoy D, Copland E, et al
    Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.
    Lancet. 2021;398:1803-1810.
    PubMed     Abstract available
    
    
    
61. SAMARASEKERA U
    Monica Peek: addressing diabetes health disparities.
    Lancet. 2021;398:1792.
    PubMed    
    
    
    
62. CAVENDER MA, Wirka RC
    Blood pressure lowering in the prevention of type 2 diabetes.
    Lancet. 2021;398:1778-1779.
    PubMed    
    
    
    
63. HELLER SR, Durrant A, Tandon N
    Insulin, the patient, and the health professional.
    Lancet. 2021;398:1785-1786.
    PubMed    
    
    
    
64. THE LANCET
    100 years of insulin: a technical success but an access failure.
    Lancet. 2021;398:1777.
    PubMed    
    
    
    
65. DEVI S
    Cold comfort: getting insulin to those who need it.
    Lancet. 2021;398:1791.
    PubMed    
    
    
    October 2021
66. KHOO B, Tan TM
    Surpassing insulin glargine in type 2 diabetes with tirzepatide.
    Lancet. 2021 Oct 18. pii: S0140-6736(21)02279.
    PubMed    
    
    
    
67. DEL PRATO S, Kahn SE, Pavo I, Weerakkody GJ, et al
    Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Lancet. 2021 Oct 18. pii: S0140-6736(21)02188.
    PubMed     Abstract available
    
    
    September 2021
68. LINGVAY I, Sumithran P, Cohen RV, le Roux CW, et al
    Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation.
    Lancet. 2021 Sep 30. pii: S0140-6736(21)01919.
    PubMed     Abstract available
    
    
    June 2021
69. NORGAARD K, Schmidt S
    Is reimbursement for alerts and real-time continuous glucose monitoring needed?
    Lancet. 2021;397:2230-2232.
    PubMed    
    
    
    April 2021
70. POWELL EE, Wong VW, Rinella M
    Non-alcoholic fatty liver disease.
    Lancet. 2021 Apr 21. pii: S0140-6736(20)32511.
    PubMed     Abstract available
    
    
    March 2021
71. FIGTREE GA, Vernon ST, Hadziosmanovic N, Sundstrom J, et al
    Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Lancet. 2021;397:1085-1094.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.